After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Cullinan Therapeutics Inc is $813.59M. A total of 1.17 million shares were traded on the day, compared to an average of 531.37K shares.
In the most recent transaction, Savill Corrine sold 40,000 shares of CGEM for 16.18 per share on Feb 01 ’24. After the transaction, the Chief Business Officer now owns 165,990 company shares. In a previous transaction on Jan 29 ’24, Savill Corrine sold 40,000 shares at 14.09 per share. CGEM shares that Chief Business Officer owns now total 165,990.
Among the insiders who sold shares, Savill Corrine disposed of 21,316 shares on Jan 23 ’24 at a per-share price of $12.46. This resulted in the Chief Business Officer holding 165,990 shares of CGEM after the transaction. In another insider transaction, Savill Corrine sold 18,684 shares at $12.14 per share on Jan 22 ’24. Company shares held by the Chief Business Officer now total 165,990.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CGEM has a high of $20.62 and a low of $7.64.
As of this writing, CGEM has an earnings estimate of -$0.98 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.72 per share and a lower estimate of -$1.42. The company reported an EPS of -$1.42 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CGEM’s latest balance sheet shows that the firm has $290.47M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $11.75M in liabilities at the time. Its Book Value Per Share was $10.58, while its Total Shareholder’s Equity was $425.37M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CGEM is Buy with a score of 5.00.
